Ladenburg Thalmann Initiates Coverage On Aprea Therapeutics with Buy Rating, Announces Price Target of $2

Ladenburg Thalmann analyst Kevin DeGeeter has initiated coverage on Aprea Therapeutics (NASDAQ: APRE) with a Buy rating. The analyst has set a price target of $2 for the company's stock.